Patients were prospectively evaluated in terms of urinary symptomatology, physical examination, smoking habits, intravenous pyelography (IVP), abdominal ultrasonography (USG), Nuclear Matrix
Protein 22 (NMP22), urine cytology and NMP22 BladderChek[R] test.
Recently, measurement of the nuclear matrix
protein 22 (NMP22) in urine samples has come to the forefront as a cost-efficient point-of-care proteomic assay that could be used to detect UCB.
Contributors shed light on research into basic biology and regulatory mechanisms controlling prostate cancer growth and its implications for new therapeutic interventions, in areas including cell adhesion molecules, the use of the nuclear matrix
, and the prostate-specific membrane antigen.
The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix
protein (NMP) technology, which correlates levels of NMP's in body fluids to the presence of cancer.
However, some researchers suggest that the most convincing explanation for hyperthermia's effects is that the cellular nuclear matrix
is damaged by heat.
We have evaluated numerous potential markers for cervical cancer and believe that nuclear matrix
proteins, particularly NMP179, represent the best technology to combine with our equipment.
6,162,608 for the detection of cancer in body fluid samples, including blood, urine, spinal fluid and sputum, using the company's proprietary fluid-based nuclear matrix
The test uses the company's proprietary NMP66 blood screen, which correlates levels of nuclear matrix
protein (NMP) in body fluids with the presence of cancer.
The DNA loops, which are -60 kb in size and represent the fourth level of DNA organization, attach at their base to a central nuclear matrix
Several studies have demonstrated the effectiveness of nuclear matrix
protein 22 (NMP22) as a diagnostic tool for detection and surveillance of bladder cancer.
Newton, MA; 617-928-0820), a company specializing in products designed to manage and screen cancer, announced that it has been issued United States Patent 5,882,876 by the United States Patent and Trademark Office for its invention using a nuclear matrix
protein in Matritech's urine-based NMP22 Test Kit for bladder cancer.
Matritech's NMP22 Test Kit measures the level of a specific nuclear matrix
protein associated with bladder cancer to accurately detect disease.